MESNA for Transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 9 adverse event reports in the FDA FAERS database where MESNA was used for Transitional cell carcinoma.
Most Reported Side Effects for MESNA
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Febrile neutropenia | 707 | 14.5% | 47 | 532 |
| Pyrexia | 352 | 7.2% | 46 | 249 |
| Off label use | 299 | 6.1% | 51 | 138 |
| Cystitis haemorrhagic | 294 | 6.0% | 9 | 23 |
| Disease progression | 273 | 5.6% | 151 | 9 |
| Neutropenia | 238 | 4.9% | 36 | 96 |
| Encephalopathy | 226 | 4.6% | 27 | 148 |
| Vomiting | 200 | 4.1% | 36 | 120 |
| Death | 184 | 3.8% | 184 | 13 |
| Pancytopenia | 179 | 3.7% | 20 | 96 |
| Diarrhoea | 177 | 3.6% | 35 | 110 |
| Sepsis | 173 | 3.5% | 77 | 80 |
| Bacterial infection | 172 | 3.5% | 151 | 23 |
| Nausea | 166 | 3.4% | 20 | 81 |
| Anaemia | 163 | 3.3% | 16 | 89 |
Other Indications for MESNA
Prophylaxis (566)
Product used for unknown indication (554)
Acute lymphocytic leukaemia (502)
Infection prophylaxis (204)
Diffuse large b-cell lymphoma (200)
Non-hodgkin's lymphoma (113)
B-cell lymphoma (91)
Burkitt's lymphoma (88)
Ewing's sarcoma (88)
Neuroblastoma (85)
Other Drugs Used for Transitional cell carcinoma
PEMBROLIZUMAB (1,951)
ENFORTUMAB VEDOTIN-EJFV (1,179)
GEMCITABINE (825)
ATEZOLIZUMAB (788)
CISPLATIN (672)
ENFORTUMAB VEDOTIN (649)
NIVOLUMAB (595)
AVELUMAB (554)
CARBOPLATIN (493)
GEMCITABINE\GEMCITABINE (255)